Expanding on their infectious disease deal, Sanofi turns to Evotec for its drug discovery expertise
French pharma giant Sanofi has turned to Evotec for some help in creating new translational efforts out of a slate of discovery programs.
The contract research group, which has forged a series of deals with biopharma partners, is setting up a new team called LAB031 for the collaboration work. The group will be responsible for the translational work behind “multiple small molecule programs through the lead optimization.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
